{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:07:55Z","timestamp":1788786475656,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.prro.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:06:08Z","timestamp":1720112768000},"page":"e362-e372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radiation Therapy Dose Response in Bulky Relapsed\/Refractory Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-5750","authenticated-orcid":false,"given":"Jonathan A.","family":"Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra D.","family":"Dreyfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"LaRiviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ima","family":"Paydar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2024.06.003_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.prro.2024.06.003_bib0002","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.06.003_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.06.003_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.06.003_bib0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2024.06.003_bib0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.06.003_bib0007","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.06.003_bib0008","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.06.003_bib0009","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/bmt.2008.408","article-title":"The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"43","author":"Hoppe","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.prro.2024.06.003_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.16541","article-title":"Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy","volume":"190","author":"Imber","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.prro.2024.06.003_bib0011","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2009.04.036","article-title":"Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era","volume":"77","author":"Biswas","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.003_bib0013","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","article-title":"Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma","volume":"91","author":"Tseng","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.003_bib0014","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.2020006028","article-title":"ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic","volume":"135","author":"Yahalom","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.prro.2024.06.003_bib0015","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.prro.2020.11.003","article-title":"Efficacy of palliative radiation therapy (RT) for chemotherapy relapsed or refractory diffuse large B-cell lymphoma: a population-based retrospective review","volume":"11","author":"Wong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0016","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0017","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0018","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0019","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0021","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0022","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hon.2368","article-title":"Low-dose radiotherapy in diffuse large B-cell lymphoma","volume":"35","author":"Furlan","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0023","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ejca.2005.04.033","article-title":"Effective palliation by low dose local radiotherapy for recurrent and\/or chemotherapy refractory non-follicular lymphoma patients","volume":"41","author":"Haas","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2024.06.003_bib0024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2008.n.032","article-title":"Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase ii study","volume":"8","author":"Murthy","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.prro.2024.06.003_bib0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1520-6823(1999)7:3<186::AID-ROI8>3.0.CO;2-2","article-title":"Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma","volume":"7","author":"Aref","year":"1999","journal-title":"Radiat Oncol Investig"},{"key":"10.1016\/j.prro.2024.06.003_bib0026","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.06.003_bib0027","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.06.210","article-title":"Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas","volume":"61","author":"Girinsky","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.003_bib0028","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2019-129624","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.prro.2024.06.003_bib0029","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.003_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/tlcr.2017.03.07","article-title":"Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)","volume":"6","author":"Flynn","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.prro.2024.06.003_bib0031","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation Therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.003_bib0032","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.prro.2024.06.003_bib0033","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2024.06.003_bib0034","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pain.2005.10.033","article-title":"The analgesic effect of low dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuro-mediators of nociception","volume":"120","author":"Vit","year":"2006","journal-title":"Pain"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024001449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024001449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:15:02Z","timestamp":1725023702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850024001449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1879850024001449"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2024.06.003","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy Dose Response in Bulky Relapsed\/Refractory Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}